Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,3792438,peak plasma oxaprozin concentration,"No significant differences existed among the four treatment conditions in peak plasma oxaprozin concentration (86 micrograms/ml), volume of distribution (0.23 l/kg), time of peak concentration (3.7 h after dosage), or elimination half-life (54 h).","Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792438/),[μg] / [ml],86,1264,DB00991,Oxaprozin
,3792438,volume of distribution,"No significant differences existed among the four treatment conditions in peak plasma oxaprozin concentration (86 micrograms/ml), volume of distribution (0.23 l/kg), time of peak concentration (3.7 h after dosage), or elimination half-life (54 h).","Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792438/),[l] / [kg],0.23,1265,DB00991,Oxaprozin
,3792438,time of peak concentration,"No significant differences existed among the four treatment conditions in peak plasma oxaprozin concentration (86 micrograms/ml), volume of distribution (0.23 l/kg), time of peak concentration (3.7 h after dosage), or elimination half-life (54 h).","Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792438/),h,3.7,1266,DB00991,Oxaprozin
,3792438,elimination half-life,"No significant differences existed among the four treatment conditions in peak plasma oxaprozin concentration (86 micrograms/ml), volume of distribution (0.23 l/kg), time of peak concentration (3.7 h after dosage), or elimination half-life (54 h).","Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792438/),h,54,1267,DB00991,Oxaprozin
,3792438,oral clearance,"Oxaprozin oral clearance was significantly lower (by 20%) during both the cimetidine and ranitidine trials versus control (0.047 vs 0.047 vs 0.059 ml/min/kg), but clearance during acetaminophen was not significantly different from control.","Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792438/),[ml] / [kg·min],0.047,1268,DB00991,Oxaprozin
,3792438,oral clearance,"Oxaprozin oral clearance was significantly lower (by 20%) during both the cimetidine and ranitidine trials versus control (0.047 vs 0.047 vs 0.059 ml/min/kg), but clearance during acetaminophen was not significantly different from control.","Interaction of oxaprozin with acetaminophen, cimetidine, and ranitidine. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3792438/),[ml] / [kg·min],0.059,1269,DB00991,Oxaprozin
exceeded,7357792,Recovery of,"Recovery of radioactivity in excreta, mostly in urine, exceeded 90%.",Metabolism and kinetics of oxaprozin in normal subjects. ,Radioactivity-Q8,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7357792/),%,90,18750,DB00991,Oxaprozin
,7357792,clearance (Clp),"The slow clearance (Clp), 0.08 to 0.12 1/hr, was almost entirely due to biotransformation and the plasma half-lifes, which ranged from 49 to 69 hr, reflected the small Clp.",Metabolism and kinetics of oxaprozin in normal subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7357792/),[1] / [h],0.08 to 0.12,18751,DB00991,Oxaprozin
,7357792,plasma half-lifes,"The slow clearance (Clp), 0.08 to 0.12 1/hr, was almost entirely due to biotransformation and the plasma half-lifes, which ranged from 49 to 69 hr, reflected the small Clp.",Metabolism and kinetics of oxaprozin in normal subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7357792/),h,49 to 69,18752,DB00991,Oxaprozin
,7357792,volume of distribution (VD beta,The small volume of distribution (VD beta = 8 to 9 1) indicates limited extravascular distribution.,Metabolism and kinetics of oxaprozin in normal subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7357792/),1,8 to 9,18753,DB00991,Oxaprozin
,9115051,elimination half-lives (t 1/2,"The nonsteroidal antiinflammatory drugs (NSAIDs) oxaprozin and piroxicam have long elimination half-lives (t 1/2 approximately 55 hours), permitting once-daily dose regimens.","Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115051/),h,55,55465,DB00991,Oxaprozin
,9115051,t1/2,"Mean single-dose kinetic parameters of oxaprozin versus piroxicam did not differ more than +/-14% (t1/2, 53.0 versus 57.4 hours; apparent oral clearance adjusted for 70-kg body weight [Clpo], 0.139 versus 0.121 L/hr; apparent volume of distribution adjusted for 70-kg body weight [Vd/F]; 10.2 L versus 9.13 L).","Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115051/),h,53.0,55466,DB00991,Oxaprozin
,9115051,t1/2,"Mean single-dose kinetic parameters of oxaprozin versus piroxicam did not differ more than +/-14% (t1/2, 53.0 versus 57.4 hours; apparent oral clearance adjusted for 70-kg body weight [Clpo], 0.139 versus 0.121 L/hr; apparent volume of distribution adjusted for 70-kg body weight [Vd/F]; 10.2 L versus 9.13 L).","Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115051/),h,57.4,55467,DB00991,Oxaprozin
,9115051,apparent oral clearance,"Mean single-dose kinetic parameters of oxaprozin versus piroxicam did not differ more than +/-14% (t1/2, 53.0 versus 57.4 hours; apparent oral clearance adjusted for 70-kg body weight [Clpo], 0.139 versus 0.121 L/hr; apparent volume of distribution adjusted for 70-kg body weight [Vd/F]; 10.2 L versus 9.13 L).","Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115051/),[l] / [h],0.139,55468,DB00991,Oxaprozin
,9115051,apparent oral clearance,"Mean single-dose kinetic parameters of oxaprozin versus piroxicam did not differ more than +/-14% (t1/2, 53.0 versus 57.4 hours; apparent oral clearance adjusted for 70-kg body weight [Clpo], 0.139 versus 0.121 L/hr; apparent volume of distribution adjusted for 70-kg body weight [Vd/F]; 10.2 L versus 9.13 L).","Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115051/),[l] / [h],0.121,55469,DB00991,Oxaprozin
,9115051,apparent volume of distribution,"Mean single-dose kinetic parameters of oxaprozin versus piroxicam did not differ more than +/-14% (t1/2, 53.0 versus 57.4 hours; apparent oral clearance adjusted for 70-kg body weight [Clpo], 0.139 versus 0.121 L/hr; apparent volume of distribution adjusted for 70-kg body weight [Vd/F]; 10.2 L versus 9.13 L).","Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115051/),l,10.2,55470,DB00991,Oxaprozin
,9115051,apparent volume of distribution,"Mean single-dose kinetic parameters of oxaprozin versus piroxicam did not differ more than +/-14% (t1/2, 53.0 versus 57.4 hours; apparent oral clearance adjusted for 70-kg body weight [Clpo], 0.139 versus 0.121 L/hr; apparent volume of distribution adjusted for 70-kg body weight [Vd/F]; 10.2 L versus 9.13 L).","Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics. ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115051/),l,9.13,55471,DB00991,Oxaprozin
,9115051,Post-steady-state apparent t 1/2,Post-steady-state apparent t 1/2 of the total and unbound drugs of approximately 62 hours were similarly prolonged with piroxicam but differed substantially with oxaprozin (50.6 hours [total drug] versus 23.8 hours [unbound drug]).,"Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115051/),h,62,55472,DB00991,Oxaprozin
,9115051,Post-steady-state apparent t 1/2,Post-steady-state apparent t 1/2 of the total and unbound drugs of approximately 62 hours were similarly prolonged with piroxicam but differed substantially with oxaprozin (50.6 hours [total drug] versus 23.8 hours [unbound drug]).,"Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115051/),h,50.6,55473,DB00991,Oxaprozin
,9115051,Post-steady-state apparent t 1/2,Post-steady-state apparent t 1/2 of the total and unbound drugs of approximately 62 hours were similarly prolonged with piroxicam but differed substantially with oxaprozin (50.6 hours [total drug] versus 23.8 hours [unbound drug]).,"Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9115051/),h,23.8,55474,DB00991,Oxaprozin
,3566846,elimination half-life,"Oxaprozin elimination half-life was not different between controls and CHF patients (63 vs 69 h), but peak serum levels were lower (79 vs 63 micrograms/ml, p less than 0.01), apparent volume of distribution was larger (0.22 vs 0.29 l/kg, p less than 0.05) and clearance tended to be higher, although not significantly so, (0.042 vs 0.053 ml/min/kg) in CHF patients.",Oxaprozin pharmacokinetics in patients with congestive heart failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3566846/),h,63,119174,DB00991,Oxaprozin
,3566846,elimination half-life,"Oxaprozin elimination half-life was not different between controls and CHF patients (63 vs 69 h), but peak serum levels were lower (79 vs 63 micrograms/ml, p less than 0.01), apparent volume of distribution was larger (0.22 vs 0.29 l/kg, p less than 0.05) and clearance tended to be higher, although not significantly so, (0.042 vs 0.053 ml/min/kg) in CHF patients.",Oxaprozin pharmacokinetics in patients with congestive heart failure. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3566846/),h,69,119175,DB00991,Oxaprozin
,3566846,peak serum levels,"Oxaprozin elimination half-life was not different between controls and CHF patients (63 vs 69 h), but peak serum levels were lower (79 vs 63 micrograms/ml, p less than 0.01), apparent volume of distribution was larger (0.22 vs 0.29 l/kg, p less than 0.05) and clearance tended to be higher, although not significantly so, (0.042 vs 0.053 ml/min/kg) in CHF patients.",Oxaprozin pharmacokinetics in patients with congestive heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3566846/),[μg] / [ml],79,119176,DB00991,Oxaprozin
,3566846,peak serum levels,"Oxaprozin elimination half-life was not different between controls and CHF patients (63 vs 69 h), but peak serum levels were lower (79 vs 63 micrograms/ml, p less than 0.01), apparent volume of distribution was larger (0.22 vs 0.29 l/kg, p less than 0.05) and clearance tended to be higher, although not significantly so, (0.042 vs 0.053 ml/min/kg) in CHF patients.",Oxaprozin pharmacokinetics in patients with congestive heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3566846/),[μg] / [ml],63,119177,DB00991,Oxaprozin
,3566846,apparent volume of distribution,"Oxaprozin elimination half-life was not different between controls and CHF patients (63 vs 69 h), but peak serum levels were lower (79 vs 63 micrograms/ml, p less than 0.01), apparent volume of distribution was larger (0.22 vs 0.29 l/kg, p less than 0.05) and clearance tended to be higher, although not significantly so, (0.042 vs 0.053 ml/min/kg) in CHF patients.",Oxaprozin pharmacokinetics in patients with congestive heart failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3566846/),[l] / [kg],0.22,119178,DB00991,Oxaprozin
,3566846,apparent volume of distribution,"Oxaprozin elimination half-life was not different between controls and CHF patients (63 vs 69 h), but peak serum levels were lower (79 vs 63 micrograms/ml, p less than 0.01), apparent volume of distribution was larger (0.22 vs 0.29 l/kg, p less than 0.05) and clearance tended to be higher, although not significantly so, (0.042 vs 0.053 ml/min/kg) in CHF patients.",Oxaprozin pharmacokinetics in patients with congestive heart failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3566846/),[l] / [kg],0.29,119179,DB00991,Oxaprozin
,3566846,clearance,"Oxaprozin elimination half-life was not different between controls and CHF patients (63 vs 69 h), but peak serum levels were lower (79 vs 63 micrograms/ml, p less than 0.01), apparent volume of distribution was larger (0.22 vs 0.29 l/kg, p less than 0.05) and clearance tended to be higher, although not significantly so, (0.042 vs 0.053 ml/min/kg) in CHF patients.",Oxaprozin pharmacokinetics in patients with congestive heart failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3566846/),[ml] / [kg·min],0.042,119180,DB00991,Oxaprozin
,3566846,clearance,"Oxaprozin elimination half-life was not different between controls and CHF patients (63 vs 69 h), but peak serum levels were lower (79 vs 63 micrograms/ml, p less than 0.01), apparent volume of distribution was larger (0.22 vs 0.29 l/kg, p less than 0.05) and clearance tended to be higher, although not significantly so, (0.042 vs 0.053 ml/min/kg) in CHF patients.",Oxaprozin pharmacokinetics in patients with congestive heart failure. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3566846/),[ml] / [kg·min],0.053,119181,DB00991,Oxaprozin
,3566846,peak free oxaprozin serum levels,"After correction for individual values of free fraction, groups did not differ in peak free oxaprozin serum levels (0.20 vs 0.26 micrograms/ml), unbound volume of distribution (92 vs 83 l/kg), or unbound clearance (17.5 vs 15.0 ml/min/kg).",Oxaprozin pharmacokinetics in patients with congestive heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3566846/),[μg] / [ml],0.20,119182,DB00991,Oxaprozin
,3566846,peak free oxaprozin serum levels,"After correction for individual values of free fraction, groups did not differ in peak free oxaprozin serum levels (0.20 vs 0.26 micrograms/ml), unbound volume of distribution (92 vs 83 l/kg), or unbound clearance (17.5 vs 15.0 ml/min/kg).",Oxaprozin pharmacokinetics in patients with congestive heart failure. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3566846/),[μg] / [ml],0.26,119183,DB00991,Oxaprozin
,3566846,unbound volume of distribution,"After correction for individual values of free fraction, groups did not differ in peak free oxaprozin serum levels (0.20 vs 0.26 micrograms/ml), unbound volume of distribution (92 vs 83 l/kg), or unbound clearance (17.5 vs 15.0 ml/min/kg).",Oxaprozin pharmacokinetics in patients with congestive heart failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3566846/),[l] / [kg],92,119184,DB00991,Oxaprozin
,3566846,unbound volume of distribution,"After correction for individual values of free fraction, groups did not differ in peak free oxaprozin serum levels (0.20 vs 0.26 micrograms/ml), unbound volume of distribution (92 vs 83 l/kg), or unbound clearance (17.5 vs 15.0 ml/min/kg).",Oxaprozin pharmacokinetics in patients with congestive heart failure. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3566846/),[l] / [kg],83,119185,DB00991,Oxaprozin
,3566846,unbound clearance,"After correction for individual values of free fraction, groups did not differ in peak free oxaprozin serum levels (0.20 vs 0.26 micrograms/ml), unbound volume of distribution (92 vs 83 l/kg), or unbound clearance (17.5 vs 15.0 ml/min/kg).",Oxaprozin pharmacokinetics in patients with congestive heart failure. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3566846/),[ml] / [kg·min],17.5,119186,DB00991,Oxaprozin
,3566846,unbound clearance,"After correction for individual values of free fraction, groups did not differ in peak free oxaprozin serum levels (0.20 vs 0.26 micrograms/ml), unbound volume of distribution (92 vs 83 l/kg), or unbound clearance (17.5 vs 15.0 ml/min/kg).",Oxaprozin pharmacokinetics in patients with congestive heart failure. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3566846/),[ml] / [kg·min],15.0,119187,DB00991,Oxaprozin
,23865335,AUC0-->264h,"AUC0-->264h were (4 917. 44 +/- 629. 57) microg . h . mL-1 and (4 604. 30+/-737. 83) microg . h . mL-1, respectively; Cmax were (52. 34+/-7. 68) microg . mL-1 and (48. 66+/-4. 87) microg .",[Determination of oxaprozin in human plasma with high performance liquid chromatography (HPLC) and its application]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23865335/),[h·μg] / [ml],4 917. 44,126466,DB00991,Oxaprozin
,23865335,AUC0-->264h,"AUC0-->264h were (4 917. 44 +/- 629. 57) microg . h . mL-1 and (4 604. 30+/-737. 83) microg . h . mL-1, respectively; Cmax were (52. 34+/-7. 68) microg . mL-1 and (48. 66+/-4. 87) microg .",[Determination of oxaprozin in human plasma with high performance liquid chromatography (HPLC) and its application]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23865335/),[h·μg] / [ml],4 604. 30,126467,DB00991,Oxaprozin
,23865335,Cmax,"AUC0-->264h were (4 917. 44 +/- 629. 57) microg . h . mL-1 and (4 604. 30+/-737. 83) microg . h . mL-1, respectively; Cmax were (52. 34+/-7. 68) microg . mL-1 and (48. 66+/-4. 87) microg .",[Determination of oxaprozin in human plasma with high performance liquid chromatography (HPLC) and its application]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23865335/),[μg] / [ml],52. 34,126468,DB00991,Oxaprozin
,23865335,Cmax,"AUC0-->264h were (4 917. 44 +/- 629. 57) microg . h . mL-1 and (4 604. 30+/-737. 83) microg . h . mL-1, respectively; Cmax were (52. 34+/-7. 68) microg . mL-1 and (48. 66+/-4. 87) microg .",[Determination of oxaprozin in human plasma with high performance liquid chromatography (HPLC) and its application]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23865335/),μg,48. 66,126469,DB00991,Oxaprozin
,23865335,Tmax,"mL-1, respectively; Tmax were (18. 70+/-2.27) h and (19. 30+/-1. 63) h, respectively; The relative bioavailability of test preparation was 94.0% +/- 13. 7%.",[Determination of oxaprozin in human plasma with high performance liquid chromatography (HPLC) and its application]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23865335/),h,18. 70,126470,DB00991,Oxaprozin
,23865335,Tmax,"mL-1, respectively; Tmax were (18. 70+/-2.27) h and (19. 30+/-1. 63) h, respectively; The relative bioavailability of test preparation was 94.0% +/- 13. 7%.",[Determination of oxaprozin in human plasma with high performance liquid chromatography (HPLC) and its application]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23865335/),h,19. 30,126471,DB00991,Oxaprozin
,23865335,relative bioavailability,"mL-1, respectively; Tmax were (18. 70+/-2.27) h and (19. 30+/-1. 63) h, respectively; The relative bioavailability of test preparation was 94.0% +/- 13. 7%.",[Determination of oxaprozin in human plasma with high performance liquid chromatography (HPLC) and its application]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23865335/),%,94.0,126472,DB00991,Oxaprozin
,7060332,intrinsic clearance (Clint),"Consequently, unbound drug kinetic parameters, including intrinsic clearance (Clint) and V88du of unbound drug were reduced from 2.9 l/hr/kg and 193 l/kg in normal subjects to approximately 1.6 l/hr/kg and 91 l/kg in azotemic patients.",Oxaprozin disposition in renal disease. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7060332/),[l] / [h·kg],2.9,153678,DB00991,Oxaprozin
,7060332,intrinsic clearance (Clint),"Consequently, unbound drug kinetic parameters, including intrinsic clearance (Clint) and V88du of unbound drug were reduced from 2.9 l/hr/kg and 193 l/kg in normal subjects to approximately 1.6 l/hr/kg and 91 l/kg in azotemic patients.",Oxaprozin disposition in renal disease. ,CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7060332/),[l] / [h·kg],1.6,153679,DB00991,Oxaprozin
,7060332,V88du of unbound drug,"Consequently, unbound drug kinetic parameters, including intrinsic clearance (Clint) and V88du of unbound drug were reduced from 2.9 l/hr/kg and 193 l/kg in normal subjects to approximately 1.6 l/hr/kg and 91 l/kg in azotemic patients.",Oxaprozin disposition in renal disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7060332/),[l] / [kg],193,153680,DB00991,Oxaprozin
,7060332,V88du of unbound drug,"Consequently, unbound drug kinetic parameters, including intrinsic clearance (Clint) and V88du of unbound drug were reduced from 2.9 l/hr/kg and 193 l/kg in normal subjects to approximately 1.6 l/hr/kg and 91 l/kg in azotemic patients.",Oxaprozin disposition in renal disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7060332/),[l] / [kg],91,153681,DB00991,Oxaprozin
,8973987,Half-lives,"Half-lives after single-dose administration for total and unbound drug determined from 24 to 240 hours and from 24 to 72 hours, respectively, were dose independent for total drug, but dose dependent for unbound drug.",Inverse nonlinear pharmacokinetics of total and protein unbound drug (oxaprozin): clinical and pharmacokinetic implications. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8973987/),h,24 to 240,162668,DB00991,Oxaprozin
,8973987,Half-lives,"Half-lives after single-dose administration for total and unbound drug determined from 24 to 240 hours and from 24 to 72 hours, respectively, were dose independent for total drug, but dose dependent for unbound drug.",Inverse nonlinear pharmacokinetics of total and protein unbound drug (oxaprozin): clinical and pharmacokinetic implications. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8973987/),h,24 to 72,162669,DB00991,Oxaprozin
,8973987,Half-lives,Half-lives after multiple-dose administration measured from 24 to 48 hours in study II decreased further.,Inverse nonlinear pharmacokinetics of total and protein unbound drug (oxaprozin): clinical and pharmacokinetic implications. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8973987/),h,24,162670,DB00991,Oxaprozin
,3220091,volume of distribution,"Mean pharmacokinetic variables in control and conjugated estrogen groups were: volume of distribution, 15.1 vs 14.1 l; elimination half-life, 59.8 vs 54.2 h; clearance, 3.2 vs 3.1 ml/min; peak plasma concentration, 84.8 vs 90.7 micrograms/ml, respectively.",Pharmacokinetics of oxaprozin in women receiving conjugated estrogen. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3220091/),l,15.1,186037,DB00991,Oxaprozin
,3220091,volume of distribution,"Mean pharmacokinetic variables in control and conjugated estrogen groups were: volume of distribution, 15.1 vs 14.1 l; elimination half-life, 59.8 vs 54.2 h; clearance, 3.2 vs 3.1 ml/min; peak plasma concentration, 84.8 vs 90.7 micrograms/ml, respectively.",Pharmacokinetics of oxaprozin in women receiving conjugated estrogen. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3220091/),l,14.1,186038,DB00991,Oxaprozin
,3220091,elimination half-life,"Mean pharmacokinetic variables in control and conjugated estrogen groups were: volume of distribution, 15.1 vs 14.1 l; elimination half-life, 59.8 vs 54.2 h; clearance, 3.2 vs 3.1 ml/min; peak plasma concentration, 84.8 vs 90.7 micrograms/ml, respectively.",Pharmacokinetics of oxaprozin in women receiving conjugated estrogen. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3220091/),h,59.8,186039,DB00991,Oxaprozin
,3220091,elimination half-life,"Mean pharmacokinetic variables in control and conjugated estrogen groups were: volume of distribution, 15.1 vs 14.1 l; elimination half-life, 59.8 vs 54.2 h; clearance, 3.2 vs 3.1 ml/min; peak plasma concentration, 84.8 vs 90.7 micrograms/ml, respectively.",Pharmacokinetics of oxaprozin in women receiving conjugated estrogen. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3220091/),h,54.2,186040,DB00991,Oxaprozin
,3220091,clearance,"Mean pharmacokinetic variables in control and conjugated estrogen groups were: volume of distribution, 15.1 vs 14.1 l; elimination half-life, 59.8 vs 54.2 h; clearance, 3.2 vs 3.1 ml/min; peak plasma concentration, 84.8 vs 90.7 micrograms/ml, respectively.",Pharmacokinetics of oxaprozin in women receiving conjugated estrogen. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3220091/),[ml] / [min],3.2,186041,DB00991,Oxaprozin
,3220091,clearance,"Mean pharmacokinetic variables in control and conjugated estrogen groups were: volume of distribution, 15.1 vs 14.1 l; elimination half-life, 59.8 vs 54.2 h; clearance, 3.2 vs 3.1 ml/min; peak plasma concentration, 84.8 vs 90.7 micrograms/ml, respectively.",Pharmacokinetics of oxaprozin in women receiving conjugated estrogen. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3220091/),[ml] / [min],3.1,186042,DB00991,Oxaprozin
,3220091,peak plasma concentration,"Mean pharmacokinetic variables in control and conjugated estrogen groups were: volume of distribution, 15.1 vs 14.1 l; elimination half-life, 59.8 vs 54.2 h; clearance, 3.2 vs 3.1 ml/min; peak plasma concentration, 84.8 vs 90.7 micrograms/ml, respectively.",Pharmacokinetics of oxaprozin in women receiving conjugated estrogen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3220091/),[μg] / [ml],84.8,186043,DB00991,Oxaprozin
,3220091,peak plasma concentration,"Mean pharmacokinetic variables in control and conjugated estrogen groups were: volume of distribution, 15.1 vs 14.1 l; elimination half-life, 59.8 vs 54.2 h; clearance, 3.2 vs 3.1 ml/min; peak plasma concentration, 84.8 vs 90.7 micrograms/ml, respectively.",Pharmacokinetics of oxaprozin in women receiving conjugated estrogen. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3220091/),[μg] / [ml],90.7,186044,DB00991,Oxaprozin
,3220091,time of peak concentration,"However, the time of peak concentration (8.9 vs 4.0 h) was significantly longer in the control group than in the conjugated estrogen group, respectively (p less than 0.05).",Pharmacokinetics of oxaprozin in women receiving conjugated estrogen. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3220091/),h,8.9,186045,DB00991,Oxaprozin
,3220091,time of peak concentration,"However, the time of peak concentration (8.9 vs 4.0 h) was significantly longer in the control group than in the conjugated estrogen group, respectively (p less than 0.05).",Pharmacokinetics of oxaprozin in women receiving conjugated estrogen. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3220091/),h,4.0,186046,DB00991,Oxaprozin
,15324530,oral bioavailability,"Oxaprozin has a high oral bioavailability (95%), with peak plasma concentrations at 3 to 5 hours after dosing.",Oxaprozin: kinetic and dynamic profile in the treatment of pain. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15324530/),%,95,215232,DB00991,Oxaprozin
,6480879,peak plasma concentrations (Cmax,"No statistically significant differences were noted between kinetic parameters obtained in the fasting and post-prandial states for mean peak plasma concentrations (Cmax, 103 vs. 109 micrograms/ml), absorption rate constants (ka, 1.1 vs. 0.8 h-1), or total AUC (7042 vs. 7066 micrograms/ml X hr).",Effects of food on oxaprozin bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6480879/),[μg] / [ml],103,220325,DB00991,Oxaprozin
,6480879,peak plasma concentrations (Cmax,"No statistically significant differences were noted between kinetic parameters obtained in the fasting and post-prandial states for mean peak plasma concentrations (Cmax, 103 vs. 109 micrograms/ml), absorption rate constants (ka, 1.1 vs. 0.8 h-1), or total AUC (7042 vs. 7066 micrograms/ml X hr).",Effects of food on oxaprozin bioavailability. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6480879/),[μg] / [ml],109,220326,DB00991,Oxaprozin
,6480879,absorption rate constants (ka,"No statistically significant differences were noted between kinetic parameters obtained in the fasting and post-prandial states for mean peak plasma concentrations (Cmax, 103 vs. 109 micrograms/ml), absorption rate constants (ka, 1.1 vs. 0.8 h-1), or total AUC (7042 vs. 7066 micrograms/ml X hr).",Effects of food on oxaprozin bioavailability. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6480879/),1/[h],1.1,220327,DB00991,Oxaprozin
,6480879,absorption rate constants (ka,"No statistically significant differences were noted between kinetic parameters obtained in the fasting and post-prandial states for mean peak plasma concentrations (Cmax, 103 vs. 109 micrograms/ml), absorption rate constants (ka, 1.1 vs. 0.8 h-1), or total AUC (7042 vs. 7066 micrograms/ml X hr).",Effects of food on oxaprozin bioavailability. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6480879/),1/[h],0.8,220328,DB00991,Oxaprozin
,6480879,total AUC,"No statistically significant differences were noted between kinetic parameters obtained in the fasting and post-prandial states for mean peak plasma concentrations (Cmax, 103 vs. 109 micrograms/ml), absorption rate constants (ka, 1.1 vs. 0.8 h-1), or total AUC (7042 vs. 7066 micrograms/ml X hr).",Effects of food on oxaprozin bioavailability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6480879/),[μg] / [h·ml],7042,220329,DB00991,Oxaprozin
,6480879,total AUC,"No statistically significant differences were noted between kinetic parameters obtained in the fasting and post-prandial states for mean peak plasma concentrations (Cmax, 103 vs. 109 micrograms/ml), absorption rate constants (ka, 1.1 vs. 0.8 h-1), or total AUC (7042 vs. 7066 micrograms/ml X hr).",Effects of food on oxaprozin bioavailability. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6480879/),[μg] / [h·ml],7066,220330,DB00991,Oxaprozin
,6480879,lag time t0,"Compared with doses administered during fasting, postprandial doses led to a delay in the onset of absorption in the gastrointestinal tract (lag time t0, 24 vs. 9 min), but not in the peak time (tmax approximately 5 hours).",Effects of food on oxaprozin bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6480879/),min,24,220331,DB00991,Oxaprozin
,6480879,lag time t0,"Compared with doses administered during fasting, postprandial doses led to a delay in the onset of absorption in the gastrointestinal tract (lag time t0, 24 vs. 9 min), but not in the peak time (tmax approximately 5 hours).",Effects of food on oxaprozin bioavailability. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6480879/),min,9,220332,DB00991,Oxaprozin
,6480879,tmax,"Compared with doses administered during fasting, postprandial doses led to a delay in the onset of absorption in the gastrointestinal tract (lag time t0, 24 vs. 9 min), but not in the peak time (tmax approximately 5 hours).",Effects of food on oxaprozin bioavailability. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6480879/),h,5,220333,DB00991,Oxaprozin
,6480879,mean residence time t,"Oxaprozin's mean residence time t was slightly shorter for subjects in the postprandial state (72 hours) than for those in fasting state (73 hours), probably because of the intrasubject variability in half-life (48 vs. 50 hours).",Effects of food on oxaprozin bioavailability. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6480879/),h,72,220334,DB00991,Oxaprozin
,6480879,mean residence time t,"Oxaprozin's mean residence time t was slightly shorter for subjects in the postprandial state (72 hours) than for those in fasting state (73 hours), probably because of the intrasubject variability in half-life (48 vs. 50 hours).",Effects of food on oxaprozin bioavailability. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6480879/),h,73,220335,DB00991,Oxaprozin
,6480879,half-life,"Oxaprozin's mean residence time t was slightly shorter for subjects in the postprandial state (72 hours) than for those in fasting state (73 hours), probably because of the intrasubject variability in half-life (48 vs. 50 hours).",Effects of food on oxaprozin bioavailability. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6480879/),h,48,220336,DB00991,Oxaprozin
,6480879,half-life,"Oxaprozin's mean residence time t was slightly shorter for subjects in the postprandial state (72 hours) than for those in fasting state (73 hours), probably because of the intrasubject variability in half-life (48 vs. 50 hours).",Effects of food on oxaprozin bioavailability. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6480879/),h,50,220337,DB00991,Oxaprozin
,3986088,half-life,Elimination also was slow with a mean half-life of 59 h (range 36 to 92 h).,Oxaprozin pharmacokinetics in the elderly. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3986088/),h,59,243684,DB00991,Oxaprozin
,3986088,free fraction,"Owing in part to extensive protein binding (mean free fraction 0.0023%), oxaprozin distribution was limited, with apparent volume of distribution averaging 0.25 l/kg.",Oxaprozin pharmacokinetics in the elderly. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3986088/),%,0.0023,243685,DB00991,Oxaprozin
,3986088,apparent volume of distribution,"Owing in part to extensive protein binding (mean free fraction 0.0023%), oxaprozin distribution was limited, with apparent volume of distribution averaging 0.25 l/kg.",Oxaprozin pharmacokinetics in the elderly. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3986088/),[l] / [kg],0.25,243686,DB00991,Oxaprozin
